Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mineralocorticoid receptor (MR), encoded by the NR3C2 gene, is a nuclear receptor that functions as a ligand-activated transcription factor. It plays a critical role in regulating sodium and water balance, blood pressure, and electrolyte homeostasis. While aldosterone is the primary physiological ligand, MR also binds glucocorticoids. Tissue-specific expression of 11β-HSD2 ensures aldosterone selectivity in epithelial tissues. Aberrant MR activation is implicated in cardiovascular and metabolic disorders, making it a therapeutic target for hypertension and heart failure. Antagonists like spironolactone and eplerenone are used clinically to block excessive mineralocorticoid signaling.
Ligand binding induces receptor translocation to the nucleus, dimerization, binding to hormone response elements on DNA, and recruitment of transcriptional machinery to regulate target gene expression. Antagonists block ligand binding and prevent receptor activation.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mineralocorticoid Receptor.